Alan S. Coates

52.7k total citations · 10 hit papers
297 papers, 23.6k citations indexed

About

Alan S. Coates is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Alan S. Coates has authored 297 papers receiving a total of 23.6k indexed citations (citations by other indexed papers that have themselves been cited), including 178 papers in Oncology, 147 papers in Cancer Research and 81 papers in Genetics. Recurrent topics in Alan S. Coates's work include Breast Cancer Treatment Studies (139 papers), Estrogen and related hormone effects (68 papers) and Cancer Treatment and Pharmacology (42 papers). Alan S. Coates is often cited by papers focused on Breast Cancer Treatment Studies (139 papers), Estrogen and related hormone effects (68 papers) and Cancer Treatment and Pharmacology (42 papers). Alan S. Coates collaborates with scholars based in Australia, Switzerland and Italy. Alan S. Coates's co-authors include Aron Goldhirsch, Richard D. Gelber, Beat Thürlimann, Hans-Jörg Senn, W. C. Wood, Karen N. Price, Monica Castiglione‐Gertsch, Marco Colleoni, John Forbes and John H. Glick and has published in prestigious journals such as Nature, New England Journal of Medicine and The Lancet.

In The Last Decade

Alan S. Coates

289 papers receiving 22.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

2011 2.9k citations Aron Goldhirsch, W. C. Wood et al. Annals of Oncology profile →
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

2009 1.0k citations Aron Goldhirsch, Richard D. Gelber et al. Annals of Oncology profile →
Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005

2005 886 citations Aron Goldhirsch, John H. Glick et al. Annals of Oncology profile →
On the receiving end—patient perception of the side-effects of cancer chemotherapy

1983 806 citations Alan S. Coates, R. M. Fox et al. profile →
Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

2007 693 citations Alan S. Coates, Aparna Keshaviah et al. Journal of Clinical Oncology profile →
Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007

2007 680 citations Aron Goldhirsch, W. C. Wood et al. Annals of Oncology profile →
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

2009 581 citations Mitch Dowsett, Jack Cuzick et al. Journal of Clinical Oncology profile →
Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer

2003 537 citations Aron Goldhirsch, Richard D. Gelber et al. Journal of Clinical Oncology profile →
Improving the Quality of Life during Chemotherapy for Advanced Breast Cancer

1987 419 citations Alan S. Coates, Robert L. Woods et al. profile →
Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V

2016 378 citations Marco Colleoni, Zhuoxin Sun et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Alan S. Coates

Since Specialization

Citations

This map shows the geographic impact of Alan S. Coates's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan S. Coates with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan S. Coates more than expected).

Fields of papers citing papers by Alan S. Coates

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan S. Coates. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan S. Coates. The network helps show where Alan S. Coates may publish in the future.

Co-authorship network of co-authors of Alan S. Coates

This figure shows the co-authorship network connecting the top 25 collaborators of Alan S. Coates. A scholar is included among the top collaborators of Alan S. Coates based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan S. Coates. Alan S. Coates is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Genomic Characterization and Prognostic Significance of Human Epidermal Growth Factor Receptor 2–Low, Hormone Receptor–Positive, Early Breast Cancers From the BIG 1-98 and SOFT Clinical Trials 2025 ·JCO Precision Oncology ·Stephen J. Luen, (unknown), (unknown), Peter Savas, Roswitha Kammler, Patrizia Dell’Orto, Olivia Biasi, Alan S. Coates, Richard D. Gelber, Beat Thürlimann, Marco Colleoni, Gini F. Fleming, Prudence A. Francis, Meredith M. Regan, Giuseppe Viale, Sherene Loi	1
2	Clinical behavior of recurrent hormone receptor–positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1‐98 clinical trial 2020 ·Cancer ·José Pablo Leone, Bernard F. Cole, Meredith M. Regan, Beat Thürlimann, Alan S. Coates, Manuela Rabaglio, Anita Giobbie‐Hurder, Richard D. Gelber, Bent Ejlertsen, Vernon Harvey, Patrick Neven, István Láng, Hervé Bonnefoi, Andrew Wardley, Aron Goldhirsch, Angelo Di Leo, Marco Colleoni, Inês Vaz-Luís, Nancy U. Lin	5
3	Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial 2012 ·Journal of Clinical Oncology ·Marianne Ewertz, Kathryn P. Gray, Meredith M. Regan, Bent Ejlertsen, Karen N. Price, Beat Thürlimann, Hervé Bonnefoi, John Forbes, Robert Paridaens, Manuela Rabaglio, Richard D. Gelber, Marco Colleoni, István Láng, Ian E. Smith, Alan S. Coates, Aron Goldhirsch, Henning T. Mouridsen	102
4	Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer 2010 ·Journal of Clinical Oncology ·Marco Colleoni, Bernard F. Cole, Giuseppe Viale, Meredith M. Regan, Karen N. Price, Eugenio Maiorano, Mauro G. Mastropasqua, Diana Crivellari, Richard D. Gelber, Aron Goldhirsch, Alan S. Coates, Barry A. Gusterson	109
5	Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen breakdown → 2009 ·Journal of Clinical Oncology ·Mitch Dowsett, Jack Cuzick, J. N. Ingle, Alan S. Coates, John Forbes, Judith M. Bliss, Marc Buyse, Michael Baum, Aman U. Buzdar, Marco Colleoni, R. Charles Coombes, Claire Snowdon, Michael Gnant, R. Jakesz, Manfred Kaufmann, Francesco Boccardo, Jon Godwin, Christina Davies, Richárd Pető	581
6	Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy 2009 ·Breast Cancer Research and Treatment ·Eugenio Maiorano, Meredith M. Regan, Giuseppe Viale, Mauro G. Mastropasqua, Marco Colleoni, Monica Castiglione‐Gertsch, Karen N. Price, Richard D. Gelber, Aron Goldhirsch, Alan S. Coates	34
7	Extracapsular tumor spread and the risk of local, axillary and supraclavicular recurrence in node-positive, premenopausal patients with breast cancer 2008 ·Annals of Oncology ·Guenther Gruber, Bernard F. Cole, Monica Castiglione‐Gertsch, Stig B. Holmberg, Jurij Lindtner, Rastko Golouh, J. Collins, Diana Crivellari, Beat Thürlimann, Edda Simoncini, Martin F. Fey, Richard D. Gelber, Alan S. Coates, Karen N. Price, Aron Goldhirsch, Giuseppe Viale, B.A. Gusterson	26
8	Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial 2007 ·Journal of Clinical Oncology ·Henning T. Mouridsen, Aparna Keshaviah, Alan S. Coates, Manuela Rabaglio, Monica Castiglione‐Gertsch, Zhuoxin Sun, Beat Thürlimann, L. Mauriac, John Forbes, Robert Paridaens, Richard D. Gelber, Marco Colleoni, Ian Smith, Karen N. Price, Aron Goldhirsch	93
9	Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 breakdown → 2007 ·Annals of Oncology ·Aron Goldhirsch, W. C. Wood, Richard D. Gelber, Alan S. Coates, Beat Thürlimann, Hans-Jörg Senn	680
10	Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial 2007 ·Annals of Oncology ·L. Mauriac, Aparna Keshaviah, Marc Debled, Henning T. Mouridsen, John Forbes, Beat Thürlimann, R. Paridaens, Alain Monnier, István Láng, Andrew Wardley, Jean‐Marie Nogaret, RD Gelber, Monica Castiglione‐Gertsch, K.N. Price, Alan S. Coates, Ian Smith, Giuseppe Viale, Manuela Rabaglio, (unknown), Aron Goldhirsch	106
11	Meeting highlights: International Consensus Panel on the treatment of primary breast cancer [5] (multiple letters) 2002 ·Journal of Clinical Oncology ·Richard R. Love, Aron Goldhirsch, John H. Glick, Richard D. Gelber, Alan S. Coates, Hans Senn	2
12	Desmoplastic and desmoplastic neurotropic melanoma 1998 ·Cancer ·Michael Quinn, Kerry A. Crotty, John F. Thompson, Alan S. Coates, Christopher John O'Brien, William H. McCarthy	0
13	Desmoplastic and desmoplastic neurotropic melanoma 1998 ·Cancer ·Michael J. Quinn, Kerry A. Crotty, John F. Thompson, Alan S. Coates, Christopher J. O’Brien, William H. McCarthy	194
14	International Breast Cancer Study Group Trials 1998 ·Recent results in cancer research ·Alan S. Coates	3
15	Timing of baseline quality of life assessment in an international adjuvant breast cancer trial: Its effect on patient self-estimation 1994 ·Annals of Oncology ·(unknown), Jürg Bernhard, Alan S. Coates, M. Castiglione, Harriet F. Peterson, R.D. Gelber, Carl‐Magnus Rudenstam, Aron Goldhirsch, H.-J. Senn	22
16	Changing character of cervical cancer in young women. 1989 ·BMJ ·Perry Elliott, Martin H.N. Tattersall, Malcolm Coppleson, Pamela J. Russell, Frances Wong, Alan S. Coates, H. J. Solomon, P. Bannatyne, Kenneth Atkinson, John Murray	63
17	Phase-II Study of Recombinant α ₂ -Interferon in Advanced Malignant Melanoma 1986 ·Journal of Interferon Research ·Alan S. Coates, (unknown), Peter Hersey, Cheryl E. Swanson	24
18	Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanoma 1986 ·Cancer ·Peter Hersey, Malcolm MacDonald, Christopher Hall, (unknown), Anne Edwards, Alan S. Coates, William H. McCarthy	26
19	Surgery in patients with advanced germ cell malignancy following a clinical partial response to chemotherapy 1983 ·Journal of Surgical Oncology ·Roger R. Reddel, John F. Thompson, Derek Raghavan, Martin H.N. Tattersall, John A. Levi, G. A. E. Coupland, R. M. Fox, Alan S. Coates, Robert L. Woods, Alan B. P. Ng	3
20	Immunological cross-reactivity between basic proteins of myelin and cancer. I. Lymphocyte transformation studies in immunized guinea-pigs. 1975 ·PubMed Central ·Alan S. Coates, P. R. Carnegie	10

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact